Cost sharing payments to collaboration partners recorded as expenses in research and development expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss, and cost sharing reimbursements from collaboration partners recorded as an offset to expense in research and development expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss are as follows (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Takeda Collaboration Agreement:
PTV:PGRN cost sharing (reimbursements)	$	(1,513)	$	(1,439)	$	(3,130)	$	(2,935)
ATV:TREM2 cost sharing (reimbursements)	—		(10)		—		(147)
Total Takeda cost sharing (reimbursements)(1)	(1,513)		(1,449)		(3,130)		(3,082)
Biogen Collaboration Agreement: LRRK2 cost sharing payments(2)	2,024		4,229		5,887		8,880
Net cost sharing payments (reimbursements)	$	511	$	2,780	$	2,757	$	5,798

_________________________________

(1)Cost sharing reimbursements of $1.5 million and $1.6 million were recorded as a receivable within prepaid expenses and other current assets on the Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025, respectively.

(2)Cost sharing payments due to Biogen of $2.0 million and $2.8 million were recorded within other accrued costs and current liabilities on the Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025, respectively.